Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (innate lymphoid cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: pateclizumab, baminercept | 0.81 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 10 Parkinson's papers of 4,975 | 0.69 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 10124
Sealed predictions
- LTA in dopamine neurons, braak-0.36 (p 0.344) → -0.06 (p 0.873)receipt 10130
Swarm cases
receipt 10130: LTA in dopamine neurons, braak
- power
- full sample -0.25 (p 0.319, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.25 (p 0.310, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.25 (p 0.315, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.319, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LTA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts